We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
(-0.32%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$60.5M |
| 2 |
S&P Global
SPGI
|
+$52.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$41.3M |
| 4 |
AGN
Allergan plc
AGN
|
+$38.2M |
| 5 |
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$98.3M |
| 2 |
Eli Lilly
LLY
|
+$54.1M |
| 3 |
Apple
AAPL
|
+$51.2M |
| 4 |
Fidelity National Information Services
FIS
|
+$42.9M |
| 5 |
Stryker
SYK
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Financials | 21.66% |
| 3 | Technology | 21.39% |
| 4 | Communication Services | 9.45% |
| 5 | Consumer Discretionary | 5.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Broadcom
AVGO
$1.82T
| $7.3M | 0.14% |
469,920
+204,310
| +77% | +$3.11M |
|
|
ATHN
152
DELISTED
Athenahealth, Inc.
ATHN
| $7.26M | 0.14% |
52,584
+25,359
| +93% | +$3.35M |
|
|
DYNC
153
DELISTED
Vistra Energy Corp.
DYNC
| $7M | 0.13% |
+65,000
| New | +$6.83M |
|
154
UBS Group
UBS
$170B
| $6.42M | 0.12% |
487,887
-169,867
| -26% | -$2.6M |
|
155
Box
BOX
$4.02B
| $6.26M | 0.12% |
605,745
+544,085
| +882% | +$6.51M |
|
156
Toronto Dominion Bank
TD
$198B
| $6.18M | 0.12% |
125,000
| – | – |
|
157
Synchrony
SYF
$23.7B
| $6.1M | 0.12% |
241,260
+15,588
| +7% | +$454K |
|
|
158
Eli Lilly
LLY
$1.07T
| $5.91M | 0.11% |
75,000
-718,778
| -91% | -$54.1M |
|
159
PayPal
PYPL
$49.5B
| $5.9M | 0.11% |
161,601
+4,673
| +3% | +$179K |
|
160
Mastercard
MA
$477B
| $5.9M | 0.11% |
66,940
+61,535
| +1,138% | +$5.88M |
|
161
Abbott
ABT
$180B
| $5.89M | 0.11% |
150,000
| – | – |
|
162
PennantPark Floating Rate Capital
PFLT
$681M
| $5.86M | 0.11% |
472,500
| – | – |
|
|
FRC
163
DELISTED
First Republic Bank
FRC
| $5.86M | 0.11% |
83,693
-886
| -1% | -$61.4K |
|
164
Blackstone
BX
$104B
| $5.63M | 0.11% |
229,594
+533
| +0.2% | +$14.2K |
|
|
DVAX
165
DELISTED
Dynavax Technologies
DVAX
| $5.54M | 0.1% |
379,932
-50,068
| -12% | -$856K |
|
|
PPBI
166
DELISTED
Pacific Premier Bancorp
PPBI
| $5.51M | 0.1% |
229,596
-15,353
| -6% | -$357K |
|
|
IDTI
167
DELISTED
Integrated Device Technology I
IDTI
| $5.23M | 0.1% |
260,023
-365,796
| -58% | -$7.74M |
|
|
DFS
168
DELISTED
Discover Financial Services
DFS
| $4.96M | 0.09% |
92,500
-6,410
| -6% | -$349K |
|
169
PNC Financial Services
PNC
$100B
| $4.87M | 0.09% |
59,800
| – | – |
|
170
Regeneron Pharmaceuticals
REGN
$68.8B
| $4.86M | 0.09% |
13,909
+4,862
| +54% | +$1.87M |
|
171
US Bancorp
USB
$99.6B
| $4.78M | 0.09% |
118,586
-875
| -0.7% | -$36.4K |
|
172
Biogen
BIIB
$29.9B
| $4.66M | 0.09% |
19,266
+3,660
| +23% | +$965K |
|
173
RingCentral
RNG
$4.05B
| $4.45M | 0.08% |
225,810
+43,416
| +24% | +$822K |
|
174
Ziff Davis
ZD
$1.9B
| $4.22M | 0.08% |
76,905
+31,365
| +69% | +$1.74M |
|
|
XLNX
175
DELISTED
Xilinx Inc
XLNX
| $4.15M | 0.08% |
89,974
+84,827
| +1,648% | +$3.88M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.
Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.
- Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
- Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
- Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
- Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
- Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
- Polar Capital opened 35 new positions and closed 35 in Q2 2016.
- Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.
Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.